Protagenic Therapeutics, Inc. (PTIX) Q3 2025 Financial Report: Key Investor Insights

Overview

Protagenic Therapeutics, Inc. (“PTIX”) has released its Form 10-Q for the quarter ended December 31, 2025. This report provides a comprehensive look at the company’s financial position, recent corporate actions, and key developments that may impact shareholders and the PTIX share price.

Key Points from the Report

• Quarterly Report Filed: PTIX has filed all required reports for the past 12 months and confirms compliance with Section 13 or 15(d) of the Securities Exchange Act of 1934.
• Reporting Status: PTIX is classified as a non-accelerated filer and a smaller reporting company. It is not an emerging growth company or shell company. As of March 5, 2026, there were 1,810,208 shares of common stock outstanding, with a par value of \$0.0001 per share.
• Securities Registered: Common Stock (par value \$0.0001) and Common Stock Purchase Warrants (Ticker: PTIXW) are registered and listed on the Nasdaq Capital Market.
• Financial Position:
  • Total Assets: \$4,431,101 as of December 31, 2025, a significant increase from \$89,093 as of March 31, 2025.
  • Stockholders’ Equity: The report lists various classes of preferred stock, including Series C1 Convertible Preferred Stock with 950,000 shares issued and outstanding as of December 31, 2025.
  • Commitments and Contingencies: The company discloses commitments and contingencies but reports no material amounts as of the quarter end.
• Corporate Actions:
  • Reverse Split: The financial statements reference rounding from a reverse split, indicating a recent share consolidation. This is often a material event and may affect share liquidity and pricing.
  • Bio Acquisition: PTIX completed the acquisition of Phytanix Bio, Inc., with assets acquired being recorded under the company’s balance sheet. The acquisition involved issuance of various series of preferred stock and warrants.
  • Warrant Exercises & New Issues: Multiple entries show stock issued during the period due to warrant exercises and new capital raises, potentially affecting the share count and dilution.
• Share-Based Compensation: The company is actively granting employee stock options and reporting share-based compensation expenses, indicating ongoing efforts to incentivize management and staff.
• Other Notable Disclosures:
  • Compliance: PTIX confirms electronic submission of all required Interactive Data Files.
  • Market Risk: The report includes a section on Quantitative and Qualitative Disclosures about Market Risk, which may be relevant to investors monitoring volatility and exposure.
  • Risk Factors: Item 1A of the report is dedicated to risk factors, which shareholders should review for any new or material changes.

Potential Price Sensitive Information

• Significant Asset Increase: The jump in total assets from \$89,093 to \$4,431,101 is material and likely due to the Phytanix Bio acquisition. This may affect valuation, investor confidence, and share price.
• Reverse Stock Split: Share consolidation can affect trading dynamics and investor perception. The reverse split may be aimed at maintaining Nasdaq listing requirements or improving share structure.
• Preferred Stock Issuance: The issuance of 950,000 Series C1 Convertible Preferred Shares and other preferred classes introduces new dilution risks and changes to voting/control structures.
• Acquisition Activity: The acquisition of Phytanix Bio, Inc. could open new business lines or revenue streams, but also introduces integration risks. Investors should monitor subsequent financial performance.
• Warrant Exercises and New Share Issues: These actions increase the outstanding share count and may dilute current shareholders, but also raise capital for further operations.

What Shareholders Should Watch

1. Integration of Phytanix Bio: Monitor for operational synergies, revenue growth, and any material changes in expenses following the acquisition.
2. Share Structure Changes: Track the impact of the reverse split and new preferred shares on share liquidity and potential dilution.
3. Continued Capital Raises: The company’s ongoing warrant exercises and new share issues suggest a need for capital; this could be positive if funds are deployed productively, but negative if it signals cash flow issues.
4. Nasdaq Compliance: The reverse split and share structure changes may be related to Nasdaq listing standards—any risk of delisting could be price sensitive.
5. Risk Factors: Investors should review the risk disclosures for any new material threats to the company’s business model or financial position.

Conclusion

Protagenic Therapeutics, Inc. has undergone significant corporate and financial changes in the latest quarter, including a major acquisition, a reverse stock split, and the issuance of new preferred shares. These actions have materially altered the company’s asset base and share structure, and are likely to impact the PTIX share price. Shareholders and potential investors are advised to review the full 10-Q for further details and monitor company communications for post-acquisition integration updates and any additional capital raises.

Disclaimer: This article is based on publicly available SEC filings and is intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The reporter has made reasonable efforts to highlight all material information but cannot guarantee completeness or accuracy. Protagenic Therapeutics, Inc. may make further disclosures or filings that could materially impact the share price.

View Protagenic Therapeutics, Inc.new Historical chart here